Tempus AI, Inc. (NASDAQ:TEM) Major Shareholder Sells $9,301,500.00 in Stock

Tempus AI, Inc. (NASDAQ:TEM) major shareholder Bradley A. Keywell sold 265,000 shares of the stock in a transaction dated Friday, January 17th. The shares were sold at an average price of $35.10, for a total transaction of $9,301,500.00. Following the completion of the transaction, the insider now directly owns 15,218,365 shares of the company’s stock, valued at approximately $534,164,611.50. The trade was a 1.71 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Tempus AI Trading Up 1.2 %

Tempus AI stock opened at $35.15 on Monday. Tempus AI, Inc. has a fifty-two week low of $22.89 and a fifty-two week high of $79.49. The company has a 50 day moving average price of $46.03 and a 200-day moving average price of $47.27. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on TEM shares. Bank of America upped their price objective on Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a research report on Friday, December 13th. Stifel Nicolaus lowered Tempus AI from a “buy” rating to a “hold” rating and increased their price target for the company from $45.00 to $65.00 in a report on Monday, November 11th. Guggenheim started coverage on shares of Tempus AI in a research note on Monday, December 9th. They set a “buy” rating and a $74.00 price objective for the company. Needham & Company LLC reissued a “buy” rating and issued a $56.00 target price on shares of Tempus AI in a research note on Tuesday, January 14th. Finally, Piper Sandler reaffirmed a “neutral” rating and set a $70.00 price target (up from $40.00) on shares of Tempus AI in a research note on Tuesday, November 12th. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $56.36.

Institutional Investors Weigh In On Tempus AI

Institutional investors and hedge funds have recently bought and sold shares of the company. NEA Management Company LLC raised its holdings in shares of Tempus AI by 17.8% in the 3rd quarter. NEA Management Company LLC now owns 5,385,979 shares of the company’s stock valued at $304,846,000 after purchasing an additional 813,169 shares in the last quarter. Novo Holdings A S bought a new position in Tempus AI in the second quarter worth approximately $142,605,000. ARK Investment Management LLC lifted its holdings in Tempus AI by 355.0% during the third quarter. ARK Investment Management LLC now owns 2,378,157 shares of the company’s stock worth $134,604,000 after buying an additional 1,855,459 shares during the period. Sumitomo Mitsui Trust Group Inc. boosted its position in Tempus AI by 1,591.2% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,217,699 shares of the company’s stock valued at $68,922,000 after acquiring an additional 1,145,698 shares in the last quarter. Finally, Franklin Resources Inc. boosted its position in Tempus AI by 1.0% during the 3rd quarter. Franklin Resources Inc. now owns 811,311 shares of the company’s stock valued at $45,920,000 after acquiring an additional 8,387 shares in the last quarter. 24.22% of the stock is owned by institutional investors.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.